drugset
drugset / Trial / NCT01767987

Ranolazine Cardioprotection in PCI

NCT01767987 ↗

Phase 2 Terminated 6 enrolled Harvey Hahn Gilead Sciences · collab
RandomizedParallel-groupTriple-blindPrevention

Summary

The investigators will test if upfront dosing of Ranolazine can reduce myocardial biomarker release (CK-MB, Troponin) post percutaneous coronary intervention (PCI).

Timeline

Start
2012-11
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ranolazine Small molecule 1000 mg Oral

Indications

acute coronary syndrome